KMID : 1140820180130030079
|
|
Urogenital Tract Infection 2018 Volume.13 No. 3 p.79 ~ p.83
|
|
Patient¡¯s Factors Correlated with Prostate Volume Recovery after 5 Alpha Reductase Inhibitor Discontinuation
|
|
Choi Kwi-Bok
Kim Byoung-Hoon Cho In-Chang Min Seung-Ki
|
|
Abstract
|
|
|
Purpose: The 5 alpha reductase inhibitor (5ARI) reduces the size of the prostate and alleviates lower urinary tract symptoms. After stopping 5ARI, the prostate quickly recovers to its pre-medication size. The purpose of this study was to investigate the factors affecting the restoration of prostate size after 5ARI discontinuation.
Materials and Methods: Between March 2009 and May 2017, patients who visited an outpatient clinic and were diagnosed with benign prostatic hyperplasia were selected and start 5ARI medication. After 6 months of medication, the patients stopped medication for 1 year. Meanwhile, we measured the prostate volumes of patients 3 times (before and after medication, after discontinuation) and divide the patients into 3 groups (maintained, intermediate, and restored) with recovered prostate volume ratio. After classification, we investigated the relationship between the variable factors (age, serum prostate-specific antigen, initial volume, reduced volume after medication) between groups.
Results: Among the 147 selected patients, the mean age and plasma PSA level were 61.6¡¾7.9 and 0.8¡¾0.6, respectively. The mean initial prostate volume was 32.3¡¾4.2 ml, which reduced to 23.2¡¾3.2 ml after medication. After one year of discontinuation, the mean volume was 31.4¡¾6.4 ml, with restoration to 101.5% of the reduced size. We noticed a tendency that patients with faster prostate volume recovery were generally older than those with slower recovery; however, this was not statistically significant. Other factors showed no relationship with prostate recovery.
Conclusions: When using 5ARI in elderly patients, continuous treatment seems better than intermittent treatment. If discontinuation is needed, short term follow-up is recommended.
|
|
KEYWORD
|
|
Benign prostate hyperplasia, 5 alpha reductase inhibitor
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|